Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Hepatitis C

  Free Subscription


Articles published in Gut

Retrieve available abstracts of 35 articles:
HTML format
Text format



Single Articles


    June 2017
  1. LEVANDER S, Holmstrom F, Frelin L, Ahlen G, et al
    Immune-mediated effects targeting hepatitis C virus in a syngeneic replicon cell transplantation mouse model.
    Gut. 2017 Jun 23. pii: gutjnl-2016-313579. doi: 10.1136/gutjnl-2016-313579.
    PubMed     Text format     Abstract available


  2. MAHALE P, Engels EA, Li R, Torres HA, et al
    The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection.
    Gut. 2017 Jun 20. pii: gutjnl-2017-313983. doi: 10.1136/gutjnl-2017-313983.
    PubMed     Text format     Abstract available


  3. SUN HY, Cheng PN, Tseng CY, Tsai WJ, et al
    Favouring modulation of circulating lipoproteins and lipid loading capacity by direct antiviral agents grazoprevir/elbasvir or ledipasvir/sofosbuvir treatment against chronic HCV infection.
    Gut. 2017 Jun 14. pii: gutjnl-2017-313832. doi: 10.1136/gutjnl-2017-313832.
    PubMed     Text format     Abstract available


    March 2017
  4. COLPITTS CC, Tawar RG, Mailly L, Thumann C, et al
    Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape.
    Gut. 2017 Mar 30. pii: gutjnl-2016-312577. doi: 10.1136/gutjnl-2016-312577.
    PubMed     Text format     Abstract available


  5. LAURAIN A, Kramer L, Sultanik P, Vallet-Pichard A, et al
    Mortality associated with the treatment of HCV with direct-acting antivirals.
    Gut. 2017 Mar 23. pii: gutjnl-2017-313869. doi: 10.1136/gutjnl-2017-313869.
    PubMed     Text format    


    February 2017
  6. VAN RENNE N, Roca Suarez AA, Duong FH, Gondeau C, et al
    miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis.
    Gut. 2017 Feb 3. pii: gutjnl-2016-312270. doi: 10.1136/gutjnl-2016-312270.
    PubMed     Text format     Abstract available


    January 2017
  7. MENARD A, Aherfi S, Mokhtari S, Dhiver C, et al
    Toward chronic hepatitis C eradication in HIV-positive patients, including those cirrhotic and infected with genotype 3 viruses.
    Gut. 2017 Jan 10. pii: gutjnl-2016-313431. doi: 10.1136/gutjnl-2016-313431.
    PubMed     Text format    


  8. BUDKOWSKA A
    Intriguing structure of the HCV particle.
    Gut. 2017 Jan 5. pii: gutjnl-2016-313184. doi: 10.1136/gutjnl-2016-313184.
    PubMed     Text format    


    December 2016

  9. Erratum: Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort.
    Gut. 2016;65:2060.
    PubMed     Text format    


    November 2016
  10. ROINGEARD P, Dreneau J, Meunier JC
    Unravelling the multiple roles of apolipoprotein E in the hepatitis C virus life cycle.
    Gut. 2016 Nov 3. pii: gutjnl-2016-312774. doi: 10.1136/gutjnl-2016-312774.
    PubMed     Text format    


    October 2016
  11. YOKOKAWA H, Higashino A, Suzuki S, Moriyama M, et al
    Induction of humoural and cellular immunity by immunisation with HCV particle vaccine in a non-human primate model.
    Gut. 2016 Oct 26. pii: gutjnl-2016-312208. doi: 10.1136/gutjnl-2016-312208.
    PubMed     Text format     Abstract available


  12. PIVER E, Boyer A, Gaillard J, Bull A, et al
    Ultrastructural organisation of HCV from the bloodstream of infected patients revealed by electron microscopy after specific immunocapture.
    Gut. 2016 Oct 11. pii: gutjnl-2016-311726. doi: 10.1136/gutjnl-2016-311726.
    PubMed     Text format     Abstract available


    September 2016
  13. CROUCHET E, Lefevre M, Verrier ER, Oudot MA, et al
    Extracellular lipid-free apolipoprotein E inhibits HCV replication and induces ABCG1-dependent cholesterol efflux.
    Gut. 2016 Sep 8. pii: gutjnl-2015-311289. doi: 10.1136/gutjnl-2015-311289.
    PubMed     Text format     Abstract available


  14. WELZEL TM, Petersen J, Herzer K, Ferenci P, et al
    Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort.
    Gut. 2016 Sep 7. pii: gutjnl-2016-312444. doi: 10.1136/gutjnl-2016-312444.
    PubMed     Text format     Abstract available


    August 2016
  15. BEILSTEIN F, Lemasson M, Pene V, Rainteau D, et al
    Lysophosphatidylcholine acyltransferase 1 is downregulated by hepatitis C virus: impact on production of lipo-viro-particles.
    Gut. 2016 Aug 31. pii: gutjnl-2016-311508. doi: 10.1136/gutjnl-2016-311508.
    PubMed     Text format     Abstract available


  16. HUTIN YJ, Wiktor SZ
    Prioritising treatment among people who inject drugs in order to eliminate hepatitis C: addressing reluctance with sound economic analyses.
    Gut. 2016 Aug 26. pii: gutjnl-2016-312636. doi: 10.1136/gutjnl-2016-312636.
    PubMed     Text format    


  17. EL-KHAYAT HR, Fouad YM, Maher M, El-Amin H, et al
    Efficacy and safety of sofosbuvir plus simeprevir therapy in Egyptian patients with chronic hepatitis C: a real-world experience.
    Gut. 2016 Aug 10. pii: gutjnl-2016-312012. doi: 10.1136/gutjnl-2016-312012.
    PubMed     Text format     Abstract available


    July 2016
  18. LIU CH, Lin CC, Hsu WC, Chung CY, et al
    Highly bioavailable silibinin nanoparticles inhibit HCV infection.
    Gut. 2016 Jul 19. pii: gutjnl-2016-312019. doi: 10.1136/gutjnl-2016-312019.
    PubMed     Text format     Abstract available


  19. WELZEL TM, Nelson DR, Morelli G, Di Bisceglie A, et al
    Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study.
    Gut. 2016 Jul 13. pii: gutjnl-2016-311609. doi: 10.1136/gutjnl-2016-311609.
    PubMed     Text format     Abstract available


  20. SHIMAKAWA Y, Bonnard P, El Kassas M, Abdel-Hamid M, et al
    Diagnostic accuracy of the gamma-glutamyl transpeptidase to platelet ratio to predict liver fibrosis in Egyptian patients with HCV genotype 4.
    Gut. 2016 Jul 7. pii: gutjnl-2016-312326. doi: 10.1136/gutjnl-2016-312326.
    PubMed     Text format    


    April 2016
  21. FISCHER J, Weber AN, Bohm S, Dickhofer S, et al
    Sex-specific effects of TLR9 promoter variants on spontaneous clearance of HCV infection.
    Gut. 2016 Apr 21. pii: gutjnl-2015-310239. doi: 10.1136/gutjnl-2015-310239.
    PubMed     Text format     Abstract available


  22. SCOTT N, McBryde ES, Thompson A, Doyle JS, et al
    Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model.
    Gut. 2016 Apr 12. pii: gutjnl-2016-311504. doi: 10.1136/gutjnl-2016-311504.
    PubMed     Text format     Abstract available


    January 2016
  23. SERTI E, Park H, Keane M, O'Keefe AC, et al
    Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFNalpha.
    Gut. 2016 Jan 4. pii: gutjnl-2015-310033. doi: 10.1136/gutjnl-2015-310033.
    PubMed     Text format     Abstract available


    December 2015
  24. VARCHETTA S, Mele D, Lombardi A, Oliviero B, et al
    Lack of Siglec-7 expression identifies a dysfunctional natural killer cell subset associated with liver inflammation and fibrosis in chronic HCV infection.
    Gut. 2015 Dec 16. pii: gutjnl-2015-310327. doi: 10.1136/gutjnl-2015-310327.
    PubMed     Text format     Abstract available


    November 2015
  25. PRENTOE J, Verhoye L, Velazquez Moctezuma R, Buysschaert C, et al
    HVR1-mediated antibody evasion of highly infectious in vivo adapted HCV in humanised mice.
    Gut. 2015 Nov 20. pii: gutjnl-2015-310300. doi: 10.1136/gutjnl-2015-310300.
    PubMed     Text format     Abstract available


  26. ZOULIM F, Liang TJ, Gerbes AL, Aghemo A, et al
    Hepatitis C virus treatment in the real world: optimising treatment and access to therapies.
    Gut. 2015;64:1824-33.
    PubMed     Text format     Abstract available


    August 2015
  27. VERCAUTEREN K, Brown RJ, Mesalam AA, Doerrbecker J, et al
    Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice.
    Gut. 2015 Aug 25. pii: gutjnl-2014-309045. doi: 10.1136/gutjnl-2014-309045.
    PubMed     Text format     Abstract available


  28. STOHR S, Costa R, Sandmann L, Westhaus S, et al
    Host cell mTORC1 is required for HCV RNA replication.
    Gut. 2015 Aug 14. pii: gutjnl-2014-308971. doi: 10.1136/gutjnl-2014-308971.
    PubMed     Text format     Abstract available


  29. DEUFFIC-BURBAN S, Yazdanpanah Y
    Fair prices for new direct-acting antiviral agents (DAAs) to make treatment for all affordable.
    Gut. 2015;64:1190-1.
    PubMed     Text format    


    July 2015
  30. KENG CT, Sze CW, Zheng D, Zheng Z, et al
    Characterisation of liver pathogenesis, human immune responses and drug testing in a humanised mouse model of HCV infection.
    Gut. 2015 Jul 6. pii: gutjnl-2014-307856. doi: 10.1136/gutjnl-2014-307856.
    PubMed     Text format     Abstract available


    June 2015
  31. MAJOR ME
    Hepatitis C: new clues to better vaccines?
    Gut. 2015 Jun 19. pii: gutjnl-2015-309829. doi: 10.1136/gutjnl-2015-309829.
    PubMed     Text format    


  32. VON DELFT A, Humphreys IS, Brown A, Pfafferott K, et al
    The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design.
    Gut. 2015 Jun 19. pii: gutjnl-2014-308724. doi: 10.1136/gutjnl-2014-308724.
    PubMed     Text format     Abstract available


  33. TESTONI B, Durantel D, Lebosse F, Fresquet J, et al
    Ribavirin restores IFNalpha responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes.
    Gut. 2015 Jun 16. pii: gutjnl-2014-309011. doi: 10.1136/gutjnl-2014-309011.
    PubMed     Text format     Abstract available


  34. ZHANG DY, Goossens N, Guo J, Tsai MC, et al
    A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection.
    Gut. 2015 Jun 4. pii: gutjnl-2015-309655. doi: 10.1136/gutjnl-2015-309655.
    PubMed     Text format     Abstract available


    July 2014
  35. ARNDT S, Wacker E, Dorn C, Koch A, et al
    Enhanced expression of BMP6 inhibits hepatic fibrosis in non-alcoholic fatty liver disease.
    Gut. 2014 Jul 10. pii: gutjnl-2014-306968. doi: 10.1136/gutjnl-2014-306968.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: